The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Background Renin–angiotensin system (RAS) inhibitors—including angiotensin-converting–
enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs)—slow the progression …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Chronic kidney disease (CKD) is defined by a low glomerular filtration rate or high
albuminuria, and affects 15–20% of adults globally. CKD increases the risk of various …